GLP-1 drugs cut teens’ BMI by 18.5% in a 72-week trial
☕ Includes a question for the family ↓
GLP-1 drugs (Ozempic, Wegovy, Mounjaro)Part of a story we are following · 8 articles · See every update
If you are raising a teenager with obesity, this is encouraging news. A weekly medicine in the family of GLP-1 drugs worked well in a carefully run trial.
In a study of 160 teens with obesity or overweight, whose average age was 14.6 years, those who took tirzepatide for 72 weeks saw their BMI fall 18.5%, while BMI rose 0.5% in teens given a placebo. Everyone in the study also got healthy lifestyle support.
How the study worked
This was a randomized, double-blind trial, which means chance decided who got the medicine and neither the teens nor the researchers knew who got what. It ran at 31 medical research centers and hospitals in Canada, the Czech Republic, Israel, Italy, Poland, and the US. A total of 109 teens received tirzepatide and 51 received a placebo, an injection with no medicine in it. The results were published on November 15, 2026 in JAMA. The study followed the teens for 72 weeks, so it cannot say what happens over longer stretches of time.
All the teens had obesity or overweight along with at least 1 health problem linked to weight. On average, they were 14.6 years old and had a BMI of 38.6. BMI is a number that compares weight to height. Slightly more than half were girls (61.9%).
What they found
The main result was a big drop in BMI. After 72 weeks, teens on tirzepatide had an 18.5% lower BMI than where they started. Teens on placebo had a BMI that went up by 0.5%.
The researchers also counted how many teens reached a meaningful drop. Among teens on tirzepatide, 79.6% lowered their BMI by at least 5%. In the placebo group, 28.5% did.
The researchers checked 10 other key results, such as body weight, waist size, and how well the teens could move and do daily activities. All 10 came out in favor of tirzepatide over placebo.
The most common side effects were stomach and digestion problems. Most were mild to moderate.
What is tirzepatide?
Tirzepatide is a once-weekly injection. It copies two natural gut hormones, GIP and GLP-1, that help tell your brain you are full after eating. It is part of the wider group people call GLP-1 drugs. Before this study, it was approved for obesity in adults, and there was little information on how it worked in adolescents.
What you can do today
Take a little time to write down some things about your teen: how they usually eat, how they move during the week, and any health problems a doctor has mentioned. Bring the list to your teen’s next pediatrician visit and ask what options fit your family, including whether medicine could be part of the plan.
For clinicians and researchers
Design: Phase 3, randomized, double-blind trial at 31 centers in Canada, the Czech Republic, Israel, Italy, Poland, and the US. Adolescents aged 12 to younger than 18 years with obesity or overweight and at least 1 complication; n = 160, randomized 2:1 to tirzepatide (n = 109) or placebo (n = 51) for 72 weeks.
Main result: Percent change in BMI at week 72 was an 18.5% reduction with tirzepatide versus a 0.5% increase with placebo (estimated treatment difference, -19.0 [95% CI, -23.9 to -14.1] percentage points; P < .001). Gastrointestinal adverse events were most common, mostly mild to moderate.
Main limitation: The abstract reports a relatively small sample (n = 160) with 72 weeks of follow-up, so long-term efficacy, safety, and weight regain after treatment cannot be assessed.
How it fits: This extends earlier Mongevity coverage of tirzepatide, which addressed stroke outcomes in people with a heart rhythm condition and diabetes, to adolescents with obesity. Fewer strokes for people with a heart rhythm condition and diabetes on tirzepatide
Open question: Whether BMI reductions persist beyond 72 weeks, including after treatment discontinuation, and what the long-term safety profile is in adolescents remain to be tested.
Trial registry: NCT06075667
Talk about it at home
After you eat, your gut sends tiny signals up to your brain, a bit like text messages saying you have had enough. In this study, scientists wanted to learn how that signaling works for teenagers. To compare fairly, they let chance decide who went in which group, the way you might draw names from a hat.
Ask a grandparent or an older neighbor what they liked to play outside when they were young, and what mealtimes were like at their home.
Try it at home
Keep exploring
Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.
Cite this article
Mongevity Desk. GLP-1 drugs cut teens’ BMI by 18.5% in a 72-week trial. Mongevity. Published November 18, 2026. Accessed November 22, 2026. https://mongevity.science/metabolism/2026/11/glp-1-drugs-tirzepatide-teens-obesity-bmi/Mongevity Desk. GLP-1 drugs cut teens’ BMI by 18.5% in a 72-week trial [Internet]. Mongevity; 2026 Nov 18 cited 2026 Nov 22]. Available from: https://mongevity.science/metabolism/2026/11/glp-1-drugs-tirzepatide-teens-obesity-bmi/Mongevity Desk. (2026, November 18). GLP-1 drugs cut teens’ BMI by 18.5% in a 72-week trial. Mongevity. https://mongevity.science/metabolism/2026/11/glp-1-drugs-tirzepatide-teens-obesity-bmi/
<a href="https://mongevity.science/metabolism/2026/11/glp-1-drugs-tirzepatide-teens-obesity-bmi/">GLP-1 drugs cut teens’ BMI by 18.5% in a 72-week trial</a>
Free to share or quote with credit and a link.
Questions and answers
- What did the trial find about tirzepatide in teens?
- Over 72 weeks, teens on tirzepatide had an 18.5% drop in BMI, while teens on placebo had a 0.5% rise.
- Who was in the study?
- 160 teens, with an average age of 14.6 years, who had obesity or overweight and at least 1 weight-related health problem. 109 got tirzepatide and 51 got a placebo.
- What side effects did teens have?
- The most common were stomach and digestion problems, mostly mild to moderate.
- Is tirzepatide a GLP-1 drug?
- It belongs to the wider group of GLP-1 drugs. It copies two gut hormones, GLP-1 and GIP, and is taken as a once-weekly injection.





